This HTML5 document contains 73 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n12http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q73445633
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel artikull shkencor i botuar më 01 shkurt 2000 scientific article published on 01 February 2000 wüsseschaftlicher Artikel, wo im Hornig 2000 veröffentlicht worden isch im Februar 2000 veröffentlichter wissenschaftlicher Artikel наукова стаття, опублікована в лютому 2000 artículu científicu espublizáu en febreru de 2000
p:P577
wds:Q73445633-EFB61C00-B0AF-40CE-B0FF-898162E11C5B
wdt:P577
2000-02-01T00:00:00Z
p:P407
wds:Q73445633-9349A6BF-02D5-40A3-B12A-4D240E9371CB
wdt:P407
wd:Q1860
p:P2093
wds:Q73445633-06E9FE6C-9977-4EC1-8B99-A57F3E3978D2 wds:Q73445633-05C74A7D-DD30-4C3B-8957-1A3DCAF345E5 wds:Q73445633-5347082D-EA89-4FD6-B8FE-D0FCEECBC28D wds:Q73445633-2186BE7D-27D1-4B0D-9C8B-62D7190A6FE1 wds:Q73445633-36FEC7F5-D99C-42ED-A0FB-6A0B361EB5E6 wds:Q73445633-84087CC1-803C-4199-801C-99601173EF17 wds:Q73445633-5589B68E-D6DB-4FF4-B5B7-69A1CDCB723C wds:Q73445633-A4B09ABE-38FD-4C3C-8C54-C3BB219B8C2F wds:Q73445633-CBE5BCF3-A981-4B3B-A678-B677A7E5C4A2 wds:Q73445633-D84F00E1-9E37-424F-972B-40C77819D365 wds:Q73445633-CF88DC86-CE3E-45B9-A660-ADB46B656EDB wds:Q73445633-DE3BCB43-3688-4F4B-A068-F21B11D218BE
wdt:P2093
J G Klijn R Paridaens T Gamucci A Awada P Bruning J Schachter R Sylvester J Wildiers A Van Vreckem M Piccart S Houston R Coleman
rdfs:label
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over
skos:prefLabel
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over
schema:name
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over
p:P50
wds:Q73445633-BB181E87-866C-427F-AB28-22FA909307C7
wdt:P50
wd:Q60658485
p:P1476
wds:Q73445633-D1A4267D-4463-4B0F-A18F-1D4FD04AEED3
wdt:P1476
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over
p:P304
wds:Q73445633-38012A5A-F72D-4342-8F0B-60F99E2BA2BA
wdt:P304
724-733
p:P31
wds:Q73445633-5B2E93E4-F88B-4B3D-A97A-C2E0CBEFF4AD
wdt:P31
wd:Q13442814
p:P921
wds:Q73445633-B5284CEA-D661-48BE-8F71-F1B39B0CC1B8 wds:Q73445633-D6672D90-4FFF-4DD0-81CA-F946DCB5CC9C wds:Q73445633-6914AEC7-779F-4FBB-BB5D-9E54EF5B3031 wds:Q73445633-EFCF5A24-5AD4-45D2-9204-7D7C1AEBB069
wdt:P921
wd:Q12859063 wd:Q974135 wd:Q18936 wd:Q423762
p:P698
wds:Q73445633-93D7AB39-9FFC-4CAB-952F-0628EBB3AE9C
wdtn:P698
n9:10673513
wdt:P698
10673513
p:P1433
wds:Q73445633-10F5BE8E-6443-4D12-858C-D0D4FAFCE263
wdt:P1433
wd:Q400292
p:P433
wds:Q73445633-E46F2873-BFD3-47E2-B890-C67A52FC5C0E
p:P478
wds:Q73445633-B1C1FF0D-81B5-46EB-B9A6-ABE71EEF14B5
wdt:P433
4
wdt:P478
18
p:P356
wds:Q73445633-AAB52C09-E7AE-4EC8-91D2-0193840F64E5
wdtn:P356
n12:JCO.2000.18.4.724
wdt:P356
10.1200/JCO.2000.18.4.724